Genematrix Inc
KOSDAQ:109820
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
B
|
Bendigo and Adelaide Bank Ltd
OTC:BXRBF
|
AU |
Genematrix Inc
Research & Development
Genematrix Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
G
|
Genematrix Inc
KOSDAQ:109820
|
Research & Development
-₩3.1B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-6%
|
|
|
Celltrion Inc
KRX:068270
|
Research & Development
-₩208B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-14%
|
|
|
O
|
OliX Pharmaceuticals Inc
KOSDAQ:226950
|
Research & Development
-₩25.6B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
N/A
|
|
|
V
|
Voronoi Inc
KOSDAQ:310210
|
Research & Development
-₩17.9B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
11%
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Research & Development
-₩28.4B
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-35%
|
CAGR 10-Years
-31%
|
|
|
A
|
ABL Bio Inc
KOSDAQ:298380
|
Research & Development
-₩95.6B
|
CAGR 3-Years
-35%
|
CAGR 5-Years
-31%
|
CAGR 10-Years
N/A
|
|
Genematrix Inc
Glance View
GENEMATRIX, Inc. engages in the development of platform and molecular diagnostics products. The company is headquartered in Seongnam, Gyeonggi-Do and currently employs 60 full-time employees. The company went IPO on 2009-11-06. The firm operates in two segments: pharmaceutical development and diagnostic medicine. Its pharmaceutical development segment specializes in the development of restriction fragment mass polymorphism (RFMP) genotyping technology for diagnosis of hepatitis B virus (HBV), hepatitis C virus (HCV), human papillomavirus (HPV) and others. Its diagnostic medicine segment specializes in the manufacture and sale of liver-function examination reagents, and import and sale of medical equipment and reagents.
See Also
What is Genematrix Inc's Research & Development?
Research & Development
-3.1B
KRW
Based on the financial report for Dec 31, 2024, Genematrix Inc's Research & Development amounts to -3.1B KRW.
What is Genematrix Inc's Research & Development growth rate?
Research & Development CAGR 10Y
-6%
Over the last year, the Research & Development growth was 12%. The average annual Research & Development growth rates for Genematrix Inc have been -3% over the past three years , -12% over the past five years , and -6% over the past ten years .
